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Background: The development of oesophageal adenocarcinoma is generally closely associated with the presence of
a specialised intestinal-type epithelium such as that found in Barrett’s oesophagus (BO). A particular histological
condition is when the distal oesophagus showing cardiac and/or fundic mucosa without intestinal metaplasia cannot
be defined as Barrett’s mucosa [condition that we call columnar-lined oesophagus (CLO)] and up till now, there has
been no agreement in literature about the management of this condition. Aurora-A overexpression leads to
centrosome amplification, chromosomal instability and aneuploidy in mammalian cells.
Patients and methods: A prospective study was carried out on 28 consecutive patients who presented columnar
mucosa above the gastro-oesophageal junction (GOJ) at endoscopy. As controls, two more biopsies were obtained,
one on the normal-appearing squamous oesophagus above the GOJ, as far as possible from the columnar
mucosa (controls A), and one taken 1 cm below the GOJ (controls B). The Aurora-A and p53 expression levels
were analysed respectively by Quantitative Real Time PCR and immunohistochemistry.
Results: Twelve patients were affected by BO (43%) while the other 16 patients (57%) had a CLO. Nine of 28 (32%)
cases were focally positive for p53 immunostaining. All the BO/CLO samples were positive for the Aurora-A transcript
with regard to controls. Furthermore, 13 of 28 (46%) cases showed overexpression (above the median for the
whole group).
Conclusion: Due to the low number of cases, we are not at present able to state that statistically significant
quantitative differences in Aurora-A messenger RNA expression exist between CLO and BO cases with and without
dysplasia and p53-positive immunostaining. Further studies on a larger number of cases with a follow-up period are
necessary in order to establish the risk of progression and the correct management of these subjects.
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introduction
In recent years, there has been an estimation in North America
and Europe of a 40-fold increase in the risk of developing
invasive adenocarcinoma of the oesophagus[1]. The proposed
model of histological progression of this kind of tumour is
a stepwise progression recognised as a metaplasia-dysplasia-
adenocarcinoma sequence (MCS) [2]. Moreover, the
development of oesophageal adenocarcinoma (OA) is generally
closely associated with the presence of a specialised
intestinal-type epithelium such as that found in Barrett’s
oesophagus (BO) [3, 4]. BO occurs in 10%–12% of patients
with chronic gastro-oesophageal reflux. Over a period of time,
the presence of this stressful agent results in replacement of
the normal squamous epithelium by the more acid-resistant
columnar epithelium [5]. For this reason, Barrett’s mucosa is
defined as the endoscopic presence of a metaplastic mucosa
with goblet cells in the oesophagus, regardless of the length
of the segment [6]. A particular histological condition is when
the distal oesophagus showing cardiac and/or fundic mucosa
without intestinal metaplasia (IM) cannot be defined as
Barrett’s mucosa [7] and up till now, there has been no
agreement in literature about the management of this
condition. Hereafter, we refer to this condition as
columnar-lined oesophagus (CLO).
As in the molecular model proposed for colorectal cancer
progression [8], several genetic alterations have been reported
in the MCS [9]. In particular, p53 alterations have been
reported in 5%–10% of cases with indeterminate dysplasia, in
65% of those with low-grade dysplasia, in 75% of cases with
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high-grade dysplasia and in 50%–90% of OA [10–12]. The
p53 gene codifies for a nuclear phosphoprotein acting as
a transcriptional regulator which prevents proliferation of
damaged cells, in some cases inducing them to apoptosis [13].
In most normal tissues, the wild-type p53 protein is
constitutively expressed at low levels because of a short half-life
[14] due to rapid degradation, but it may accumulate in the
cell as a result of several types of stress, such as DNA damage,
hypoxia, loss of normal growth and survival signals, acidity
and inflammatory processes [15], which may occur in
different physiological or pathological situations, including
tumorigenesis. In response to these situations of stress, p53
becomes stabilised and accumulates mostly in the nucleus. By
regulating the expression of a number of genes, p53 then
induces cell cycle arrest and/or apoptosis [16]. In Barrett’s
mucosa, as a consequence of oxidative DNA damage caused by
gastro-oesophageal reflux, there is an increased percentage of
cells unable to carry out DNA repair; this is sometimes
sequentially followed by p53 gene mutation and protein
accumulation, DNA aneuploidy, dysplasia and carcinoma [17].
A new important gene correlated to cancer progression is
Aurora-A also known as serine threonine kinase 15 (STK15),
BTAK, Aurora kinase A, Aurora-2 or AIKI. This gene is
a member of the Aurora/Ip11p family and is located in
chromosome 20q13. Aurora-A is an important kinase-encoding
gene involved in centrosome duplication and distribution; its
overexpression leads to centrosome amplification,
chromosomal instability and aneuploidy in mammalian cells
[18]. Moreover, Aurora-A appears to be regulated by both
phosphorylation and dephosporylation [19]. Aurora-A
overexpression has been found in many tumour cells and
tissues including breast cancer [20], gastric cancer [21],
colorectal cancer [22], bladder cancer [23], pancreatic cancer
[24], ovarian cancer [25], prostate cancer [26] and oesophageal
squamous-cell carcinoma [27]. Up till now, however, there
have not been any studies regarding Aurora-A expression
alterations in precancerous forms such as BO or CLO,
a condition probably preceding BO.
Finally, recent studies have reported that Aurora-A and p53
activities might be related by the phosphorylation of p53 at
serine 215. This interaction would bring about the abrogation
of p53 DNA binding and transactivation activities and induce
the cells to escape apoptosis and cell cycle arrest [28, 29].
The aim of this study was to assess in a consecutive series
of 28 cases showing columnar mucosa in the oesophagus at
endoscopy, biomolecular alterations, such us Aurora-A
overexpression and p53 expression, which precede the
histological phenotype and which may help in the choice of
the clinical management of these patients.
materials and methods
patient features
A prospective study was carried out on 28 consecutive patients, Helicobacter
pylori (Hp) free and with no history of previous Hp infection, who
presented columnar mucosa above the gastro-oesophageal junction (GOJ)
at endoscopy. The GOJ was identified as the point at which the tubular
oesophagus changes to became a sack-like structure. The presence of
hiatus hernia was noted. The patients had been referred to the Oesophageal
Surgical Unit, Department of Oncology, University of Palermo for an
evaluation of their suspected gastro-oesophageal reflux disease (GORD).
They all complained of one or more symptoms such as heartburn,
regurgitation, dysphagia, otolaryngological symptoms and asthma.
tissue handling
After informed consent, four-quadrant biopsies every 2 cm, beginning at
the top of the endoscopic segment of the columnar mucosa above the
GOJ, were taken from each patient and processed within 30 min of
biopsy. As controls, two more biopsies were obtained, one on the
normal-appearing squamous oesophagus above the GOJ, as far as
possible from the columnar mucosa (Controls A), and one taken 1 cm
below the GOJ (Controls B). All the histological analysis was carried out
by one of the authors (CD). All biopsies were bisected, one half of each
sample was processed for pathological examination, and the remaining
half of the sample pool was immediately frozen and stored at 280C for
subsequent biomolecular analysis. For the pathological examination, the
samples were fixed in 10% buffered formalin and embedded in paraffin
and 5 l sections were obtained at five different levels and stained with
haematoxylin and eosin and Alcian blue periodic acid–Schiff (PAS) stain, in
order to facilitate the identification of goblet cells. IM was defined as the
presence of intestinal-type goblet cells stained blue with Alcian blue PAS
stain.
p53 immunostaining
Immunohistochemical studies were carried out by means of the
avidin–biotin complex technique. The primary monoclonal antibodies
used in this study were p53 (clone DO7) obtained from Novocastra
laboratories. Sections were cut from 10% formalin-fixed,
paraffin-embedded materials and then deparaffinised in xylene and
re-hydrated through alcohol. The immunohistochemical assay was carried
out according to the manufacturer’s instructions of Universal LSAAB
(Dako, Glostrup, Denmark). In order to improve the immunostaining,
samples were digested with 0.1% trypsin and microwaved in 10 mM citrate
buffer (pH 6.0) before incubation. As a positive control for p53, the
immunostaining was carried out on sections of rectal adenocarcinoma
which had proved to be positive in previous assessments for the above-
mentioned antibodies. Finally, negative controls without primary
antibodies were included in each run of immunohistochemistry. We
considered a nuclear staining pattern as positive for p53 immunostaining.
All cases were revised by the two pathologists (CD and AF) and only cases
in which there was interobserver agreement about the presence of low-
grade dysplasia were considered as dysplastic. Moreover, in keeping with
previous reports on p53 values in interobserver agreement of low-grade
Barrett’s dysplasia diagnosis and in the correlation with disease progression,
the presence of at least focal p53 expression was used to confirm the low-
grade dysplasia [30–32].
RNA extraction and complementary DNA synthesis
Total RNA was extracted with the use of the Rneasy Minikit (Qiagen,
Hilden Germany) according to the manufacturer’s instructions. The
extracted RNA was stored at 280C until further use. RNA integrity was
verified on the Agilent 2100 bioanalyzer with the use of the RNA 6000 Nano
assay protocol (Agilent Technologies, Palo Alto, CA). Only samples with
an RNA integrity number between 8 and 10 were analysed. For
complementary DNA (cDNA) synthesis 5 lg of total RNA were reverse
transcribed in a final volume of 50 ll with a High Capacity cDNA
Archive kit (Applied Biosystems, Foster City, CA) according to the
manufacturer’s instructions. The samples were incubated for 10 min at
25C and for 2 h at 37C on the GeneAmp 9700 Applied Biosystem
(Applied Biosystems).
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quantitative determination of Aurora-A
by Real Time RT-PCR
Real Time RT-PCR was carried out with the ABI PRISM 7900 HT Sequence
Detection System (Applied Biosystems) using the TaqMan method.
Quantification was carried out with the use of the threshold cycle (Ct)
value. For the detection of Aurora-A and for normalisation the following
predesigned primer and probe set were used: assay-on-demand Gene
Expression Product, number Hs01590514_m1, AURKA and
assay-on-demand Gene Expression Product, number 4333763F, Hu-PPIA,
(Applied Biosystems). For the PCR, 100 ng of cDNA in a final volume
of 50 ll of TaqMan Universal PCR Master Mix (Applied Biosystems)
was used according to the manufacturer’s guidelines. Each sample was
analysed in triplicate and the mean quantity of each triplicate calculated by
the ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems).
In our study, the comparative Ct method was used to quantify the
relative gene expression with the formula 22??Ct, using cyclophilin A
(Hu-PPIA) as the endogenous control. Two different control samples
were used as calibrators. Specifically, for each patient the analysis was
conducted in triplicate by comparing the Aurora-A expression levels of
columnar mucosa above the GOJ, respectively toward normal-appearing
squamous oesophagus (control A), with those 1 cm below the GOJ
columnar mucosa (control B) and then making a comparison between
the two controls.
results
histological and p53 immunohistochemical results
Table 1 shows all the pathological characteristic of the
biopsies investigated. Patients were, principally, male (19/28,
68%) with a mean age of 46 (range 27–61). Twelve patients
were affected by BO (43%) (Figure 1A) while the others
16 patients (57%) had a CLO. All the CLO samples lacked
Alcian blue-positive goblet cells at histology (Figure 1B) and
weak Alcian blue positivity was present in a few columnar cells
only in some cases (Figure 1C). The control A cases consisted
of histologically normal-appearing squamous mucosa. The
control B samples consisted of normal-appearing fundic
mucosa without goblet cells (Figure 1D). Nine of 28 (32%)
cases [five of 12 BO (42%) and four of 16 CLO (25%)] showed
some histological alterations such as pale and inconspicuous
cytoplasm of the columnar cells; reduction of the cytoplasmic
mucous production and enlarged, rounded, vescicular nuclei
with evident nucleoli, occurring without inflammation and
indicative of the so called low-grade dysplasia type II or
hyperplastic dysplasia. They were focally positive for p53
immunostaining (Figure1E, F and G). Control A cases showed
mild p53-positive immunostaining only in the basal layer of
squamous epithelium. Control B cases were devoid of
dysplastic alterations and were p53 negative (Figure 1H)
Aurora-A mRNA expression
RNA extracted from 28 samples of columnar mucosa 1 cm
above GOJ (consisting both of BO and CLO samples) and
from the two controls was analysed for Aurora-A messenger
RNA expression by Real Time RT-PCR. All the BO/CLO
samples were positive for the Aurora-A transcript with
regard to controls. In particular, the comparison of the two
controls showed the same Aurora-A expression value close to
1 for all samples while all the BO/CLO samples had a higher
Figure 1. (A) Barretts case: Alcian blue-positive goblet cells and low-
grade dysplasia. (B) Columnar-lined oesophagus (CLO) case: columnar
mucosa devoid of Alcian blue-positive goblet cells. (C) CLO case: only
weak Alcian blue positivity was present in a few columnar cells, lacking of
goblet cell morphology. (D) Control B case: normal-appearing fundic
mucosa, without goblet cells and lacking of dysplasia. (E–H) p53
immunostaining is positive both in Barretts case (E) and in CLO cases (F
and G) and is absent in control B case (H). (A–D) Alcian blue periodic
acid–Schiff staining; (E–H) p53 immunostaining. Original magnification:
(A–E) ·200; (B–D and F–H) ·100.
Table 1. Clinicopathological features of Barretts oesophagus patients
Clinicopathological features Barretts oesophagus tissue
patients, n (%)
Age (years)
£50 18 (64)
>50 10 (36)
Mean age in years (range) 47 (27–61)
Sex
Male 19 (68)
Female 9 (32)
Histotype
Columnar-lined oesophagus 16 (57)
Barretts oesophagus 12 (43)
Dysplasia
Present 9 (32)
Absent 19 (68)
Total 28
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Aurora-A expression level when compared both to the control
A and to the control B cases. Furthermore, 13\28 (46%) cases
showed overexpression (above the median for the whole
group). Figure 2 shows an example of Real Time RT-PCR
experiment of Aurora-A expression respectively in 1 cm above
GOJ columnar mucosa case and control A, belonging to the
same patient and the peptidylprolyl isomerase A (PPIA)
expression levels of all samples included in this study.
discussion
Most oesophageal tumours are adenocarcinomas (OA) which
generally arise from a MCS. Although this sequence has been
fully studied and characterised, a small percentage of OA
arise from BO. This is a precancerous form associated with
chronic GORD where squamous epithelium is replaced by
metaplastic columnar epithelium. The natural history of the
sequence BO-OA is not well known but it is likely that the
store of multiple genetic alterations gives rise to Barrett’s
oesophagus-a non-invasive neoplasia-oesophagus
adenocarcinoma (BO-NIN-OA) sequence. The diagnosis of
BO is mainly based on the presence of IM and goblet cells [33].
Nowadays, although it is well known that BO-carrier patients
show 30–125 times more risk for developing OA than the
normal population, it is still difficult to discriminate the BO
patients with a major risk of developing OA. The application
of a rigid follow-up of BO patients after the first
endoscopic–histological diagnosis is the only way to identify
the presence of OA at an early stage. In certain patients,
moreover, for instance in those with CLO, the absence of
intestinal goblet cells does not permit the inclusion of such
patients in follow-up programmes, which gives rise to an
unclear clinical management of these cases. For all these
reasons, the aim of this study is to identify the presence of
Aurora-A and p53 alterations in specific forms such us CLO
and BO with the object of assessing in these forms the
biomolecular alterations that precede the histological
phenotype and that may help in the choice of the clinical
management of such cases. These analyses have been
conducted not by means of the identification of the genetic
alteration but by the study of the different Aurora-A mRNA
and p53 protein expression levels, in order to determine their
effect directly on the RNA and/or protein.
Several sporadic tumours often show chromosomal
aberrations that precede genetic alterations and that might
give rise to histological changes and then to cancer progression.
The presence of these chromosomal alterations has, in fact,
been related to the invasive tumour. The chromosomal
aberration occurs principally in dividing cells during the
mitotic event when the chromosomes are aligned in
a metaphasic plate and are about to be segregated into two
daughter cells. Each step of this multiphase process is strictly
regulated by several checkpoints and by different proteins
with a specific role in chromosome condensation, alignment
and segregation. The alterations in mitosis will give rise to
abnormal chromosome segregation and then to cells with
Figure 2. (A) Example of Aurora kinase A expression levels in Barrett’s oesophageal (11BO) and control A (11CA) of the case number 11; (B) Cyclophillin
A (peptidylprolyl isomerase A [PPIA]) expression levels in all 22 samples analysed.
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aberrant genetic panels. This study focused on the analysis of
two proteins playing two important key roles in the cell
cycle: Aurora-A, also known as a guardian of the pole, and
p53, previously known as guardian of the genome. The first
is a serine threonine kinase which, when activated by
phosphorylation, is involved in several phases of mitosis such
us centrosome maturation, centrosome separation, mitotic
entry, bipolar spindle assembly and chromosome alignment on
the metaphase plate [34]. The Aurora-A gene is located at
chromosome 20q13, which is commonly amplified in various
epithelial malignant tumours, including breast, colon, bladder,
ovarian and pancreatic cancer and the levels of Aurora-A
mRNA and protein are also increased in such tumours [34].
Contrasting data are reported on the Aurora-A role in the
histological grade of human tumours [35–37]. Some studies,
in fact, have indicated that Aurora-A overexpression is
significantly associated with higher grade tumours and poor
prognosis, while others report that the activation and
overexpression of Aurora-A is more frequently detected in
early-stage human ovarian cancers. Up-regulation of Aurora-A
mRNA and protein were analysed by semiquantitative reverse
transcription PCR and immunohistochemistry in patients
affected by human oesophageal squamous cell carcinoma
(OSCC) and in paired normal tissues [27, 38]. These studies
have reported that Aurora-A expression, in terms of both
mRNA and protein, is elevated in OSCC tissues and that it is
correlated with distant lymph node metastasis and tumour
invasion. Furthermore, Tanaka et al. [20] report that the
up-regulation of Aurora-A protein is an independent
prognostic factor. Our study is the first study in which the
different Aurora-A expression level is analysed in the
precancerous form of the oesophagus such as in BO and in
CLO, a condition probably preceding BO.
The presence of IM with goblet cells is considered the
most significant change for the diagnosis of BO, a fact
emphasised by the dictum no goblets, no Barrett’s [33]. The
meaning of CLO devoid of goblet cells or showing only a few
Alcian blue positive, columnar cells in the malignant
transformation of BO is still debated [39–42] and there will
probably be no follow-up of these patients. Sometimes, CLO
has been considered a function of sampling error [43] that
might be reduced by increasing the number of biopsies at the
initial diagnostic endoscopy [44], by the repetition of
sampling and/or by histological assessment of more numerous
sections. In our study, all of the 28 1 cm above the GOJ
samples, both consisting of BO and of CLO cases, had a major
Aurora-A expression compared with the paired normal
squamous oesophagus and normal mucosa 1 cm below the
GOJ used as controls, while the comparison between paired
control A and control B cases always shows the same low
expression levels (data not shown). These differences in
Aurora-A expression levels in columnar mucosa above and
below GOJ make it unlikely, at least for most of the CLO
cases, that a sampling mistake is involved and indicate that
CLO may not be a completely benign mucosa, and in
addition to the goblet cells, the non-goblet elements may also
be involved in the malignant transformation of BO [39].
These preliminary results indicate that a surveillance program,
at least in this phase of the study, should be indicated for
such patients. Unfortunately, no data of follow-up are available
to assess the role of Aurora-A overexpression in BO-OA
progression. It is noteworthy that in our study, Aurora-A
mRNA was over-expressed in all the cases, whether or not
intestinal goblet cells, dysplasia and p53 positivity were present.
In this regard, it is important to consider that genetic
alterations are events preceding phenotype manifestation and
are not always immediately reflected in histological alterations.
Due to the low number of cases, we are not at present able
to state that statistically significant quantitative differences in
Aurora-A mRNA expression exist between CLO and BO cases
with and without dysplasia and p53-positive immunostaining.
This matter will be the object of our further studies on
a larger number of cases with a follow-up period in order to
establish the risk of progression and the correct management
of these subjects.
references
1. Spechler SJ, Robbins AH, Rubins HB et al. Adenocarcinoma and Barrett’s
esophagus. An overrated risk? Gastroenterology 1984; 87(4): 927–933.
2. Jankowski JA, Wright NA, Meltzer SJ et al. Molecular evolution of the
metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol
1999; 154(4): 965–973.
3. Barrett NR. Chronic peptic ulcer of the oesophagus and oesophagitis. Br J Surg
1950; 38(150): 175–182.
4. Lortat-Jacob JL. L’endobrachy-oesophage. Ann Chir 1957; 11: 1247–1254.
5. Levine DS, Rubin CE, Reid BJ, Haggitt RC. Specialized metaplastic columnar
epithelium in Barrett’s esophagus. A comparative transmission electron
microscopic study. Lab Invest 1989; 60(3): 418–432.
6. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of
Barrett’s esophagus. Am J Gastroenterol 2002; 97: 1888–1895.
7. Takubo K, Vieth M, Aryal G et al. Islands of squamous epithelium and their
surrounding mucosa in columnar-lined esophagus: a pathognomonic feature of
Barrett’s esophagus? Hum Pathol 2005; 36(3): 269–274.
8. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell
1990; 61(5): 759–767.
9. McManus DT, Olaru A, Meltzer SJ. Biomarkers of esophageal adenocarcinoma
and Barrett’s esophagus. Cancer Res 2004; 64(5): 1561–1569.
10. Casson AG, Mukhopadhyay T, Cleary KR et al. p53 gene mutations in Barrett’s
epithelium and esophageal cancer. Cancer Res 1991; 51: 4495–4499.
11. Younes M, Lebovitz RM, Lechago LV, Lechago J. p53 protein accumulation in
Barrett’s metaplasia, dysplasia and carcinoma: a follow-up study.
Gastroenterology 1993; 105: 1637–1642.
12. Hamelin R, Flejou JF, Muzeau F et al. TP53 mutations, and p53 protein
immunoreactivity in malignant and premalignant Barrett’s oesophagus.
Gastroenterology 1994; 107: 1012–1018.
13. Ryan KM, Phillips AC, Vousden KH. Regulation and function of the p53 tumor
suppressor protein. Curr Opin Cell Biol 2001; 13(3): 332–337.
14. Brown JP, Pagano M. Mechanism of p53 degradation. Biochim Biophys Acta
1997; 1332(2): 1–6.
15. Takashi T, Nakamura Y. The role of p53-target genes in human cancer. Crit Rev
Oncol Hematol 2000; 33: 1–6.
16. Ryan KM, Phillips AC, Vousden KH. Regulation and function of the p53 tumor
suppressor protein. Curr Opin Cell Biol 2001; 13(3): 332–337.
17. Younes M, Lechago J, Chakraborty S et al. Relationship between dysplasia, p53
protein accumulation, DNA ploidy, and Glut1 overexpression in Barrett
metaplasia. Scand J Gastroenterol 2000; 35(2): 131–137.
18. Dutertre S, Descamps S, Prigent C. On the role of aurora-A in centrosome
function. Oncogene 2002; 21(40): 6175–6183.
19. Meraldi P, Honda R, Nigg EA. Aurora kinases link chromosome segregation
and cell division to cancer susceptibility. Curr Opin Genet Dev 2004; 14:
29–36.
symposium article Annals of Oncology
vi114 | Agnese et al. Volume 18 | Supplement 6 | June 2007
20. Tanaka T, Kimura M, Matsunaga K et al. Centrosomal kinase AIK1 is
overexpressed in invasive ductal carcinoma of the breast. Cancer Res 1999; 59:
2041–2044.
21. Sakakura C, Hagiwara A, Yasuoka R et al. Tumour-amplified kinase BTAK is
amplified and overexpressed in gastric cancers with possible involvement in
aneuploid formation. Br J Cancer 2001; 84: 824–831.
22. Bischoff JR, Anderson L, Zhu Y et al. A homologue of Drosophila Aurora kinase is
oncogenic and amplified in human colorectal cancers. EMBO J 1998; 17:
3052–3065.
23. Sen S, Zhou H, Zhang RD et al. Amplification/overexpression of a mitotic
kinase gene in human bladder cancer. J Natl Cancer Inst 2002; 94:
1320–1329.
24. Zhu J, Abbruzzese JL, Izzo J et al. AURKA amplification, chromosome instability,
and centrosome abnormality in human pancreatic carcinoma cells. Cancer Genet
Cytogenet 2005; 159: 10–17.
25. Gritsko TM, Coppola D, Paciga JE et al. Activation and overexpression of
centrosome kinase BTAK/Aurora A, in human ovarian cancer. Clin Cancer Res
2003; 9: 1420–1426.
26. Pihan GA, Purohit A, Wallace J et al. Centrosome defects can account for cellular
and genetic changes that characterize prostate cancer progression. Cancer Res
2001; 61: 2212–2219.
27. Tanaka E, Hashimoto Y, Ito T et al. The clinical significance of Aurora-A/STK15/
BTAK expression in human esophageal squamous cell carcinoma. Clin Cancer
Res 2005; 11(5): 1827–1834.
28. Haruki N, Harano T, Masuda A et al. Persistent increase in chromosome
instability in lung cancer: possible indirect involvement of p53 inactivation. Am J
Pathol 2001; 159: 1345–1352.
29. Liu Q, Kaneko S, Yang L et al. Aurora-A abrogation of p53 DNA binding and
transactivation activity by phosphorylation of serine 215. J Biol Chem 2004; 279:
52175–52182.
30. Bian YS, Osterheld MC, Bosman FT et al. p53 gene mutation and protein
accumulation during neoplastic progression in Barrett’s esophagus. Mod Pathol
2001; 14: 397–403.
31. Skacel M, Petras RE, Rybicki LA et al. p53 expression in low grade dysplasia in
Barrett’s esophagus: correlation with interobserver agreement and disease
progression. Am J Gastroenterol 2002; 97(10): 2508–2513.
32. Weston AP, Banerjee SK, Sharma P et al. p53 protein overexpression in
low-grade dysplasia (LGD) in Barrett’s esophagus. Immunohistochemical
marker predictive of progression. Am J Gastroenterol 2001; 96: 1355–1362.
33. Batts KP. Barrett esophagus–more steps forward. Hum Pathol 2001; 32:
357–359.
34. Marumoto T, Zhang D, Saya H. Aurora-A—a guardian of poles. Nat Rev Cancer
2005; 5: 42–50.
35. Gritsko TM et al. Activation and overexpression of centrosome kinase
BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 2003; 9: 1420–1426.
36. Jeng YM, Peng SY, Lin CY, Hsu HC. Overexpression and amplification of
Aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004; 10: 2065–2071.
37. Miyoshi Y, Iwao K, Egawa C, Noguchi S. Association of centrosomal kinase
STK15/BTAK mRNA expression with chromosomal instability in human breast
cancers. Int J Cancer 2001; 92: 370–373.
38. Tong T, Zhong Y, Kong J et al. Overexpression of Aurora-A contributes to
malignant development of human esophageal squamous cell carcinoma. Clin
Cancer Res 2004; 10(21): 7304–7310.
39. Chaves P, Cardoso P, de Almeida JC et al. Non-goblet cell population of Barrett’s
esophagus: an immunohistochemical demonstration of intestinal differentiation.
Hum Pathol 1999; 30(11): 1291–1295.
40. Chandrasoma P. Controversies of the cardiac mucosa and Barrett’s oesophagus.
Histopathology 2005; 46(4): 361–373.
41. Lombard C. Controversies of the cardiac mucosa and Barrett’s oesophagus.
Histopathology 2006; 49(1): 97–98.
42. Chandrasoma P. Controversies of the cardiac mucosa and Barrett’s oesophagus.
Histopathology 2006; 49(1): 97–98.
43. Goldblum JR, Lee RG. Esophagus. In Stenberg (ed): Diagnostic Surgical
Pathology. Philadelphia, PA: Lippincott Williams & Wilkins 2004.
44. Coad RA, Shepherd NA. Barrett’s oesophagus: definition, diagnosis and
pathogenesis. Curr Diagn Pathol 2003; 9(4): 218–227.
Annals of Oncology symposium article
Volume 18 | Supplement 6 | June 2007 doi:10.1093/annonc/mdm237 | vi115
